In accordance with the generally accepted cancer-immunity cycle concept (27), these APCs subsequently drive the anti-tumorigenic responses by travelling towards the lymph nodes where they present the xeno-antigens to residing CD8α+ T-cells, priming and activating effector T-cell responses. The gene discussed is CD8A; the disease is cancer.